Difference between revisions of "Team:Sydney Australia/Design"
| Line 29: | Line 29: | ||
#please h3 { | #please h3 { | ||
| + | font-family: 'Quicksand', sans-serif; | ||
font-weight: 600; | font-weight: 600; | ||
font-size: 1.2em; | font-size: 1.2em; | ||
| Line 36: | Line 37: | ||
#please p { | #please p { | ||
| + | font-family: 'Quicksand', sans-serif; | ||
font-size: 0.9em; | font-size: 0.9em; | ||
letter-spacing: 1px; | letter-spacing: 1px; | ||
| Line 286: | Line 288: | ||
<figcaption> | <figcaption> | ||
<h3>Stabiliy</h3> | <h3>Stabiliy</h3> | ||
| − | |||
<p></p> | <p></p> | ||
</figcaption> | </figcaption> | ||
| Line 294: | Line 295: | ||
</div> | </div> | ||
<figcaption> | <figcaption> | ||
| − | <h3>Single | + | <h3>Single Chain</h3> |
| − | + | ||
<p></p> | <p></p> | ||
</figcaption> | </figcaption> | ||
| Line 304: | Line 304: | ||
<figcaption> | <figcaption> | ||
<h3>Cost Effective</h3> | <h3>Cost Effective</h3> | ||
| − | + | <p></p> | |
| − | <p> | + | |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
| Line 313: | Line 312: | ||
<figcaption> | <figcaption> | ||
<h3>Intellectual Property</h3> | <h3>Intellectual Property</h3> | ||
| − | + | <p></p> | |
| − | <p> | + | |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
| Line 321: | Line 319: | ||
</div> | </div> | ||
<figcaption> | <figcaption> | ||
| − | <h3> | + | <h3>Safety and Efficacy</h3> |
| − | + | <p></p> | |
| − | <p> | + | |
</figcaption> | </figcaption> | ||
</figure> | </figure> | ||
Revision as of 09:40, 5 October 2017
The aim of the USYD iGEM 2017 team was to address the problem of insulin inaccessibility. The design of our insulin, and its means of expression, needed to look at five key characteristics:
Stabiliy
Single Chain
Cost Effective
Intellectual Property
